



## Stellate Therapeutics Appoints Sophie Durand as Chief Executive Officer and Announces Capital Raise

*- Sophie Durand appointed Chief Executive Officer to guide Stellate Therapeutics towards clinical trials*

*- Investment from eureKARE to bring long-term expertise, financial and operational support*

**Paris, France – 18 May 2021:** Stellate Therapeutics Inc. (“the Company”, “Stellate”), a global biotechnology company developing disease-modifying therapies for neurological conditions based on molecules derived from the microbiome, is pleased to announce the appointment of Sophie Durand as Chief Executive Officer, effective immediately, and the entry of eureKARE SA to its roster of investors.

Sophie brings more than 15 years of international leadership experience across the biotechnology and finance sectors, having started her career in biotechnology investment banking at Bryan, Garnier & Co., and Kepler Capital Markets as well as financial advisory at HSBC. She then moved to the major French bank Groupe BPCE to manage financial communications and investor relations. In parallel to her work for BPCE, Sophie was actively involved with the Fonds CSP (PSC Fund), a non-profit organization that aims to support research on Primary Sclerosing Cholangitis, a rare liver disease. Passionate about the healthcare sector, Sophie also co-founded the Microbiome Foundation, a French non-profit organization financing cutting-edge research on gut microbiota in connection with chronic diseases.

**Sophie Durand, Chief Executive Officer of Stellate Therapeutics, said:** “I am thrilled to be joining Stellate at this exciting time for the business and to also welcome eureKARE as an investor. I look forward to working closely with the team as we progress our lead candidate, STL-101, towards IND-enabling studies, which will allow us to enter clinical trials in 2022. STL-101 has the potential to become a disease modifying therapy in neurodegenerative diseases and I am excited to further develop this potentially transformational treatment.”

eureKARE SA is focused on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology research field. eureKARE is guided by influential founder, Alexandre Mouradian, along with a pan-European team led by renowned biotech expert Rodolphe Besserve, who will both be joining Stellate Therapeutics’ Supervisory Board.

**Rodolphe Besserve, Chief Executive Officer of eureKARE SA, added:** “Stellate Therapeutics is at the forefront of cutting-edge research in the gut-brain axis, and we are confident that the strategic guidance of Sophie will be a key driver to the Company’s future growth, as one of the leaders in

this disruptive research field. We look forward to supporting the Company as it progresses towards the clinic.”

### **About Stellate Therapeutics**

Stellate Therapeutics is a private global biotechnology company that develops small molecules produced by the microbiome into first-in-class therapies for neurological diseases (Parkinson and Alzheimer diseases). Stellate is also evaluating a portfolio of new drug candidates in other conditions, with capabilities across discovery, screening, production and diagnostic development. For more information, visit [www.stellate-tx.com](http://www.stellate-tx.com).

### **About eureKARE**

eureKARE is a pioneering new company focused on financing and building next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology. eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports transformational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry.

eureKARE is headquartered in Luxembourg, with a presence in France & Belgium. For more information visit: <https://eurekare.eu/>

### **Contact**

#### **Stellate Therapeutics**

Sophie Durand, Chief Executive Officer  
[s.durand@stellate-tx.com](mailto:s.durand@stellate-tx.com)

#### **eureKARE SA**

Marina Shapochnik, Head Investor Relations  
[marina.shapochnik@eurekare.eu](mailto:marina.shapochnik@eurekare.eu)

#### **Consilium Strategic Communications**

Amber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs  
+44 (0) 203 709 5000  
[eurekare@consilium-comms.com](mailto:eurekare@consilium-comms.com)